130 related articles for article (PubMed ID: 28572530)
1. Assessment of GSK1904529A as a promising anti-osteosarcoma agent.
Fei HD; Yuan Q; Mao L; Chen FL; Cui ZH; Tao S; Ji F
Oncotarget; 2017 Jul; 8(30):49646-49654. PubMed ID: 28572530
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
[TBL] [Abstract][Full Text] [Related]
3. GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration.
Zhou Q; Zhang J; Cui Q; Li X; Gao G; Wang Y; Xu Y; Gao X
Mol Med Rep; 2015 Sep; 12(3):3381-3385. PubMed ID: 26035416
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
5. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.
Cao Y; Roth M; Piperdi S; Montoya K; Sowers R; Rao P; Geller D; Houghton P; Kolb EA; Gill J; Gorlick R
PLoS One; 2014; 9(8):e106249. PubMed ID: 25170759
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
8. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.
Schedlich LJ; Yenson VM; Baxter RC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):56-64. PubMed ID: 23831640
[TBL] [Abstract][Full Text] [Related]
9. Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling.
Cao Y; Yu L; Dai G; Zhang S; Zhang Z; Gao T; Guo W
Eur J Pharmacol; 2017 Jan; 794():77-84. PubMed ID: 27845066
[TBL] [Abstract][Full Text] [Related]
10. Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo.
Tarnowski M; Tkacz M; Zgutka K; Bujak J; Kopytko P; Pawlik A
BMC Cancer; 2017 Aug; 17(1):532. PubMed ID: 28793874
[TBL] [Abstract][Full Text] [Related]
11. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
12. Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Ory B; Baud'huin M; Verrecchia F; Royer BB; Quillard T; Amiaud J; Battaglia S; Heymann D; Redini F; Lamoureux F
Clin Cancer Res; 2016 May; 22(10):2520-33. PubMed ID: 26712686
[TBL] [Abstract][Full Text] [Related]
13. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
14. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
[TBL] [Abstract][Full Text] [Related]
15. Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo.
Wang Y; Fu Q; Zhao W
Mol Med Rep; 2013 Oct; 8(4):984-8. PubMed ID: 23912183
[TBL] [Abstract][Full Text] [Related]
16. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
18. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
19. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid inhibits tumor growth of human osteosarcoma by activating Smad signaling-induced osteogenic differentiation.
Yang QJ; Zhou LY; Mu YQ; Zhou QX; Luo JY; Cheng L; Deng ZL; He TC; Haydon RC; He BC
Int J Oncol; 2012 Jul; 41(1):153-60. PubMed ID: 22485251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
